Repare Therapeutics Inc Aktie News

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2025. “During the first quarter of 2025 we continued our efforts to create long-term value for our shareholders via partnering and by advancing our novel pipeline pro...

VANCOUVER--(BUSINESS WIRE)--DCx Biotherapeutics Corporation (“DCx”) today announced an agreement with Repare Therapeutics Inc. (“Repare”) (NASDAQ: RPTX) to (i) in-license Repare's discovery platform including certain program intellectual property, (ii) retain talent, (iii) acquire lease rights to laboratory facilities in Montreal and (iv) acquire laboratory equipment (the “Transaction”). Combin...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation (“DCx”), a newly-launched Canadian biotechnology company developing next generation...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that Steve Forte, Executive Vice President and Chief Financial Officer, has been appointed as President and Chief Executive Officer and to the Board of Directors effective April 11, 2025. He will serve in this new...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions.